Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?: In reply to, 'COVID-19: Immunology and treatment options', Felsenstein, Herbert McNamara et al. 2020'
- PMID: 32663514
- PMCID: PMC7354373
- DOI: 10.1016/j.clim.2020.108542
Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?: In reply to, 'COVID-19: Immunology and treatment options', Felsenstein, Herbert McNamara et al. 2020'
Conflict of interest statement
Declaration of Competing Interest JRM is a shareholder in and is an employee of EnteroBiotix Limited. BHM provides consultancy for Finch Therapeutics Group. SDG provides consultancy for EnteroBiotix Limited. JRM provides consultancy for EnteroBiotix Limited.
Comment on
-
COVID-19: Immunology and treatment options.Clin Immunol. 2020 Jun;215:108448. doi: 10.1016/j.clim.2020.108448. Epub 2020 Apr 27. Clin Immunol. 2020. PMID: 32353634 Free PMC article. Review.
References
-
- Gou W, Fu Y, Yue L, Chen G, Cai X, Shuai M et al. Gut microbiota may underlie the predisposition of healthy individuals to COVID-19. medRxiv 2020.03.22.20076091.
-
- Konturek P., Koziel J., Dieterich W., Haziri D., Wirtz S. Glowczyk et al. successful therapy of Clostridium difficile infection with fecal microbiota transplantation. J. Physiol. Pharmacol. 2016;67(6):859–866. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
